

XPhyto Therapeutics Corp.

10:10 22 Apr 2020

XPhyto Therapeutics wastes no time getting to work after infectious disease screening test deal with 3a-Diagnostics

XPhyto Therapeutics Corp (CSE:XPHY) (OTCPINK:XPHYF) has revealed that no time has been wasted following the deal struck with German firm 3a-Diagnostics - announced on Monday - to develop and commercialize oral screening tests for infectious diseases, including coronavirus (COVID-19).

XPhyto said its German subsidiary, Vektor Pharma has taken delivery of certain peptide biosensors from 3a to adapt them for use with Vektor's oral dissolvable thin film (ODF) platform.

READ: XPhyto Therapeutics partners with German biotech firm to develop coronavirus screening test

"We are very pleased to move so quickly from signing the Agreement to product development work," Professor Dr Thomas Beckert, managing director of Vektor, told investors in a statement on Wednesday.

"The XPhyto team shares 3a's vision of developing screening tools for rapid, low-cost and easy to self-administer detection of pathogens to manage infectious diseases on a population scale," he added.

The adaption of these biosensors to Vektor's ODF platform is expected to occur in several stages over around 30 days, said the firm. These stages include the application of formula to ODF (oral thin films) and analytical evaluation of ODF physical and chemical properties.

During this period, Vektor will also begin strategic planning for small-scale EU GMP test-manufacturing, said XPhyto.

This is expected to begin for trial purposes pending successful technical development of ODF biosensors for some or all of 3a's existing portfolio indications - stomatitis, periimplantitis, periodontitis, scarlet fever, and influenza.

3a, based near Stuttgart, specializes in developing, producing, and marketing point-of-care test systems.

XPhyto will retain an exclusive global license to commercialize all new products developed by 3a and a non-exclusive global license for the current products in development.

3a owns a proprietary biosensor platform while XPhyto specializes in manufacturing oral dissolvable thin film medical products through its 100%-owned subsidiary Vektor Pharma TF GmbH.

Shares in Toronto eased 2.6% to C\$3.35 each in early deals.

Price: 2.94

Market Cap: \$159.51 m

1 Year Share Price Graph



August 2019 January 2020 July 2020

Share Information

Code: XPHY

Listing: CSE

52 week High Low
3.55 0.73

Sector: Cannabis

Website: www.xphyto.com

Company Synopsis:

XPhyto is a science-based cannabis company focused on formulation, clinical validation, and emerging European markets. XPhyto's 100% owned German subsidiary, Bunker Pflanzenextrakte GmbH, has been granted a unique German cannabis cultivation and extraction licence for scientific purposes by the German Federal Institute for Drugs and Medical Devices (BfArM).

action@proactiveinvestors.com

Contact the author at giles@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of XPhyto Therapeutics Corp. named herein, including the promotion by the Company of XPhyto Therapeutics Corp. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).